212 related articles for article (PubMed ID: 34727194)
1. Inhibition of the hERG potassium channel by phenanthrene: a polycyclic aromatic hydrocarbon pollutant.
Al-Moubarak E; Shiels HA; Zhang Y; Du C; Hanington O; Harmer SC; Dempsey CE; Hancox JC
Cell Mol Life Sci; 2021 Dec; 78(23):7899-7914. PubMed ID: 34727194
[TBL] [Abstract][Full Text] [Related]
2. Structural implications of hERG K
Helliwell MV; Zhang Y; El Harchi A; Du C; Hancox JC; Dempsey CE
J Biol Chem; 2018 May; 293(18):7040-7057. PubMed ID: 29545312
[TBL] [Abstract][Full Text] [Related]
3. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological characterization of the modified hERG
Zhang Y; Dempsey CE; Hancox JC
Physiol Rep; 2020 Oct; 8(20):e14568. PubMed ID: 33091232
[TBL] [Abstract][Full Text] [Related]
6. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.
Melgari D; Brack KE; Zhang C; Zhang Y; El Harchi A; Mitcheson JS; Dempsey CE; Ng GA; Hancox JC
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25911606
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.
Melgari D; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2015 Sep; 86():42-53. PubMed ID: 26159617
[TBL] [Abstract][Full Text] [Related]
8. Serine mutation of a conserved threonine in the hERG K
Al-Moubarak E; Zhang Y; Dempsey CE; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2020 Jun; 526(4):1085-1091. PubMed ID: 32321643
[TBL] [Abstract][Full Text] [Related]
9. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
10. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656.
Siebrands CC; Schmitt N; Friederich P
Anesthesiology; 2005 Jul; 103(1):102-12. PubMed ID: 15983462
[TBL] [Abstract][Full Text] [Related]
11. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
[TBL] [Abstract][Full Text] [Related]
12. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Ridley JM; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue.
Helliwell MV; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765012
[No Abstract] [Full Text] [Related]
14. Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Physiol Rep; 2018 Sep; 6(17):e13845. PubMed ID: 30175559
[TBL] [Abstract][Full Text] [Related]
15. Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Siebrands CC; Friederich P
Anesthesiology; 2007 Mar; 106(3):523-31. PubMed ID: 17325511
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.
Ridley JM; Milnes JT; Duncan RS; McPate MJ; James AF; Witchel HJ; Hancox JC
FEBS Lett; 2006 Apr; 580(8):1999-2005. PubMed ID: 16542653
[TBL] [Abstract][Full Text] [Related]
17. Molecular determinants of hERG potassium channel inhibition by disopyramide.
El Harchi A; Zhang YH; Hussein L; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2012 Jan; 52(1):185-95. PubMed ID: 21989164
[TBL] [Abstract][Full Text] [Related]
18. The human ether-a'-go-go related gene (hERG) K+ channel blockade by the investigative selective-serotonin reuptake inhibitor CONA-437: limited dependence on S6 aromatic residues.
Alexandrou AJ; Milnes JT; Sun SZ; Fermini B; Kim SC; Jenkinson S; Leishman DJ; Witchel HJ; Hancox JC; Leaney JL
J Physiol Pharmacol; 2014 Aug; 65(4):511-23. PubMed ID: 25179083
[TBL] [Abstract][Full Text] [Related]
19. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
Milnes JT; Crociani O; Arcangeli A; Hancox JC; Witchel HJ
Br J Pharmacol; 2003 Jul; 139(5):887-98. PubMed ID: 12839862
[TBL] [Abstract][Full Text] [Related]
20. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
